AstraZeneca
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Omepral® Tablets Special Clinical Experience Investigation in Patients With Erosive Esophagitis
- Conditions
- Reflux Esophagitis
- First Posted Date
- 2009-03-11
- Last Posted Date
- 2009-07-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 10703
- Registration Number
- NCT00859287
Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2009-03-11
- Last Posted Date
- 2016-07-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1093
- Registration Number
- NCT00859898
- Locations
- 🇺🇸
Clinical Research Advantage, Inc., Tempe, Arizona, United States
🇺🇸Southland Clinical Research Center, Inc., Fountain Valley, California, United States
🇺🇸Nextphase Clinical Trials, Inc., Miami, Florida, United States
AZD1981 Midazolam CYP4503A Induction Study
- First Posted Date
- 2009-03-11
- Last Posted Date
- 2009-04-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 28
- Registration Number
- NCT00859352
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Retrospective Survey of Bone Fracture in Patients With Arimidex 1mg
- Conditions
- Breast Cancer
- First Posted Date
- 2009-03-11
- Last Posted Date
- 2009-03-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2205
- Registration Number
- NCT00859560
Pharmacokinetic Study of Daptomycin in Healthy Chinese Subjects Living in China
- Conditions
- Healthy
- First Posted Date
- 2009-03-09
- Last Posted Date
- 2010-01-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT00858325
- Locations
- 🇨🇳
Research Site, Beijing, China
Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes
- First Posted Date
- 2009-03-06
- Last Posted Date
- 2012-12-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 20
- Registration Number
- NCT00856908
- Locations
- 🇺🇸
Research Site, Chula Vista, California, United States
Subjective Well Being of Schizophrenic Patients in Greece
- Conditions
- Schizophrenia
- First Posted Date
- 2009-03-06
- Last Posted Date
- 2010-12-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 600
- Registration Number
- NCT00857064
- Locations
- 🇬🇷
Research Site, Volos, Greece
Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy
- First Posted Date
- 2009-03-06
- Last Posted Date
- 2012-11-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 127
- Registration Number
- NCT00857623
- Locations
- 🇺🇸
Reasearch Site, Albany, New York, United States
🇺🇸Reserach Site, Bella Vista, Arkansas, United States
🇺🇸Research Site, San Antonio, Texas, United States
Arimidex: Compliance and Arthralgias in Clinical Therapy (COMPACT)
- Conditions
- Breast Cancer
- First Posted Date
- 2009-03-06
- Last Posted Date
- 2012-11-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2313
- Registration Number
- NCT00857012
- Locations
- 🇩🇪
Research Site, Zwonitz, Germany
Quetiapine XR Versus Sertraline in Acute Bipolar Depression as add-on Therapy
- Conditions
- Bipolar DisorderBipolar Depression
- Interventions
- First Posted Date
- 2009-03-06
- Last Posted Date
- 2012-04-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 27
- Registration Number
- NCT00857584
- Locations
- 🇪🇸
Research Site, Vitoria, Pais Vasco, Spain